- Home
- GBDC vs AXSM Comparison
GBDC vs AXSM Comparison
Compare GBDC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBDC
- AXSM
- Stock Information
- Founded
- GBDC 2009
- AXSM 2012
- Country
- GBDC United States
- AXSM United States
- Employees
- GBDC N/A
- AXSM N/A
- Industry
- GBDC Finance: Consumer Services
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GBDC Finance
- AXSM Health Care
- Exchange
- GBDC Nasdaq
- AXSM Nasdaq
- Market Cap
- GBDC 4.0B
- AXSM 4.7B
- IPO Year
- GBDC 2010
- AXSM 2015
- Fundamental
- Price
- GBDC $15.01
- AXSM $92.22
- Analyst Decision
- GBDC Buy
- AXSM Strong Buy
- Analyst Count
- GBDC 6
- AXSM 14
- Target Price
- GBDC $16.25
- AXSM $125.93
- AVG Volume (30 Days)
- GBDC 1.4M
- AXSM 467.1K
- Earning Date
- GBDC 02-03-2025
- AXSM 11-12-2024
- Dividend Yield
- GBDC 10.43%
- AXSM N/A
- EPS Growth
- GBDC N/A
- AXSM N/A
- EPS
- GBDC 1.36
- AXSM N/A
- Revenue
- GBDC $724,677,000.00
- AXSM $338,457,000.00
- Revenue This Year
- GBDC $23.90
- AXSM $45.04
- Revenue Next Year
- GBDC N/A
- AXSM $68.05
- P/E Ratio
- GBDC $11.00
- AXSM N/A
- Revenue Growth
- GBDC 20.16
- AXSM 51.47
- 52 Week Low
- GBDC $14.05
- AXSM $64.11
- 52 Week High
- GBDC $17.72
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- GBDC 38.13
- AXSM 46.22
- Support Level
- GBDC $14.91
- AXSM $89.09
- Resistance Level
- GBDC $15.16
- AXSM $102.30
- Average True Range (ATR)
- GBDC 0.17
- AXSM 3.49
- MACD
- GBDC -0.06
- AXSM -1.16
- Stochastic Oscillator
- GBDC 10.22
- AXSM 33.16
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.